What happened
Samsung Biologics filed provisional (unaudited) consolidated results for Q3 2026: revenue of US$1.12B (+18.5% year on year), operating profit of US$482M (+1% year on year) and net income of US$295M (−21.2% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$1.12B |
|---|---|
| Revenue vs a year earlier | +18.5% |
| Operating profit | US$482M |
| Net income | US$295M |
| Period | Q3 2026 (consolidated) |
| Filed | 2026-10-21, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20261021800344 → open original filing |
Source: DART. Information only, not investment advice.